About Event
What's in Store?
Returning to Boston this November, the 7th Myeloid-Directed Therapies Summit is the only industry-led forum dedicated exclusively to translating myeloid cell research into effective therapies for cancer, inflammation, and fibrosis. With a renewed focus on translational success, clinical lessons, and functional reprogramming, this year’s Summit showcases cutting-edge insights from leaders at AbbVie, Pfizer, AstraZeneca, and leading academic institutions.
From decoding cell state heterogeneity to rethinking personalised therapies and preclinical models, don't miss the chance to shape the next generation of myeloid-targeted strategies with those redefining the field. This is where academic discovery meets clinical impact.
Explore the Full Event Guide
-
Gain clarity on the full spectrum of myeloid pathways through expert-led comparative workshops
-
Explore the rapidly evolving field of in vivo myeloid engineering with fresh insights and dedicated sessions
- The only industry-led meeting dedicated to myeloid cells across both oncology and non-oncology applications
Join Your Peers to:
Decode Myeloid Complexity:
Gain clarity on cell state heterogeneity, functional reprogramming, and therapeutic modulation across disease contexts, from immuno-oncology to chronic inflammation
Benchmark Translational Strategies & Clinical Success:
Discover how peers are overcoming regulatory skepticism post-CD47/TREM2, aligning trial designs, and bridging the preclinical-to-clinical gap
Explore the Latest in Omics & Modeling Technologies:
From spatial transcriptomics and CRISPR screens to organotypic TME models, learn how emerging platforms are driving predictive and scalable drug development
Access Brand New Clinical & Preclinical Data:
Be first to hear insights from leading biopharma and academic researchers, including brand-new updates on Clever-1, CSF1R + PARP, CD24, and CAR-M programs
Who Will You Meet?
Join a highly engaged audience of senior decision-makers, spanning Directors, VPs, and C-Level leaders, from leading biotech and pharma, alongside top academic minds and innovative solution providers, all driving the future of Myeloid-Directed Therapies.
AUDIENCE SUMMARY
Hear it From Your Peers:
"A great gathering of people with passion for macrophage biology to share and brainstorm novel therapies and concepts"
"A very enjoyable experience. Liked the venue and the food. Great that it's small conference to we get to meet everyone"
"I liked the fact that it was a small, focused meeting. I was happy with the range of topics presented. There were also plenty of opportunities for networking"
